MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock in...
$435,240K
Proceeds from employee
stock option...
$20,579K
(1830.49%↑ Y/Y)
Net cash provided by
financing activities
$432,603K
(50437.73%↑ Y/Y)
Canceled cashflow
$23,216K
Net increase
(decrease) in cash and cash...
$64,822K
(934.90%↑ Y/Y)
Canceled cashflow
$367,781K
Payments related to
contingent value rights...
$22,933K
Payment of deferred
offering costs in...
$283K
(204.30%↑ Y/Y)
Proceeds from maturities
and sales of...
$109,439K
(-38.60%↓ Y/Y)
Proceeds from sale of
in-process research and...
$40,000K
(471.43%↑ Y/Y)
Stock-based compensation
$13,512K
(-25.91%↓ Y/Y)
Change in fair value of
cvr liability
-$4,603K
(-355.72%↓ Y/Y)
Interest proceeds from
maturities of zero coupon...
$311K
(-82.33%↓ Y/Y)
Accounts payable
$30K
(-99.02%↓ Y/Y)
Net cash (used in)
provided by investing...
-$297,904K
(-477.39%↓ Y/Y)
Net cash used in
operating activities
-$69,877K
(20.19%↑ Y/Y)
Canceled cashflow
$149,439K
Canceled cashflow
$18,456K
Purchases of marketable
securities
$447,343K
(320.78%↑ Y/Y)
Gain on sale of
in-process research and...
$40,000K
(300.00%↑ Y/Y)
Net loss
-$36,200K
(55.58%↑ Y/Y)
Prepaid expenses and
other assets
$5,608K
(48.20%↑ Y/Y)
Accrued and other
liabilities
-$3,428K
(58.69%↑ Y/Y)
Net accretion of
discount on marketable...
$3,093K
(-33.56%↓ Y/Y)
Related party accounts
payable
-$4K
(99.30%↑ Y/Y)
Back
Back
Cash Flow
Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics, Inc. (SYRE)
source: myfinsight.com